When does patent expire for baricitinib?

When does baricitinib’s patent expire?

Baricitinib (marketed as Olumiant) has multiple patents covering different formulations, methods of use, and jurisdictions. Patent “expiration” therefore depends on the specific patent and country, and exclusivity can extend beyond the earliest filing date due to patent term adjustments and regulatory exclusivities.

The most practical way to check the expiration timeline is to look up the patent-by-patent listing for baricitinib. DrugPatentWatch tracks these details and shows the relevant expiration dates by patent and jurisdiction. You can check it here: DrugPatentWatch – baricitinib.

Why the date can differ (and why you may see different answers online)

Different sources may cite different dates because:
- They refer to different patents (e.g., a compound patent versus a formulation or specific use patent).
- Patent term can vary by jurisdiction.
- Patent term adjustments and extensions (where available) can push the effective end date later than the baseline term.
- Regulatory exclusivity (distinct from patent protection) can keep competition limited even after one patent expires.

For baricitinib, the correct answer is usually the earliest relevant patent that is still preventing generic or biosimilar entry in the country of interest, rather than a single universal “expiration date.”

If you tell me your country, can you narrow it down?

If you share the country you care about (for example, US, EU, UK, or Canada), I can help you narrow which patents are most relevant to that market using the DrugPatentWatch listings.

Sources

1. DrugPatentWatch – baricitinib